Business Breakingviews TV: Gilead growth
The biotech giant is spending $5.1 billion on Belgian outfit Galapagos but won’t take control. That, says Robert Cyran, means Gilead can profit from the smaller drugmaker’s successes, while limiting the risk. It’s a smart move, as both Roche and Sanofi discovered.
Business Breakingviews TV: Gilead growth Stocks: DAX highs, Daimler slows Volocopter air taxi fleet ready by 2022 -CEO Netflix U.S. growth sputters in face of rivals Wall Street pulls back on virus outbreak worries Stocks are too pricey: wealth manager Breakingviews TV: Citi’s CEO BP pulls out of Iraq's Kirkuk field: sources Predictions 2020: Greening the financial system Greening the financial system: A Breakingviews debate America's relationship with China "probably never been better" - Trump Thunberg: Pretty much nothing has been done to reduce CO2 emissions China virus fear slams European shares Boeing seeks $10 bln amid 737 MAX crisis: source MSC and French shipyard seal cruise liner 'mega' deal South African Airways says flights 'normal' as funding woes continue European shares dip as investors eye week ahead China demands release of Huawei CFO Meng Chipsafer: revolutionizing ranching one tracker at a time Davos 2020: Greta vs. Trump, businesses scored on climate action Week ahead on Wall Street: Davos, earnings for-phone-only for-tablet-portrait-up for-tablet-landscape-up for-desktop-up for-wide-desktop-up